The Medical Letter on Drugs and Therapeutics
Another Insulin Glargine (Basaglar) for Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 1/20/17: In the Dosage and Administration paragraph, we removed the word "syringe" in describing Basaglar's KwikPen device. Basaglar is not available as a prefilled syringe; it is only available as a KwikPen.

The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300 units/mL formulation of insulin glargine (Toujeo) was approved in 2015.1

INSULIN GLARGINE — A recombinant DNA analog of human insulin, insulin glargine forms microprecipitates in subcutaneous tissue, prolonging its duration of action to a mean of about 24 hours.2 It has less peak-to-trough variation and causes less nocturnal hypoglycemia than NPH insulin.

CLINICAL STUDIES — Approval of Basaglar was based on data demonstrating the clinical efficacy and safety of Lantus.3 Comparative studies have found no significant differences in the pharmacokinetics, toxicity, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Another Insulin Glargine (Basaglar) for Diabetes
Article code: 1511b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian